Molecular typing is predicated on molecular genetic screening and isn't but routinely available. Molecular subtypes and immunohistochemical surrogate markers of your tumors (HR, HER2, triple adverse) correlate in about 70%. The differentiation of luminal A and B subtypes by HR standing and p